Arvinas (ARVN) Total Current Liabilities (2017 - 2026)
Arvinas' (ARVN) quarterly Total Current Liabilities came in at $115.9 million in Q1 2026, down 45.84% year-on-year from $214.0 million in Q1 2025, and down 18.67% quarter-over-quarter from $142.5 million in Q4 2025.
Arvinas (ARVN) Total Current Liabilities (2017 - 2026) Analysis & Trends
Arvinas' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $115.9 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 45.84% year-over-year to $115.9 million in Q1 2026; TTM through Mar 2026 was $115.9 million, a 45.84% decrease from a year earlier, with the FY2025 full-year figure at $142.5 million, down 37.99% from the prior year.
- Total Current Liabilities fell to $115.9 million in Q1 2026 per ARVN's latest filing, from $142.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $347.2 million in Q2 2024 and bottomed at $115.9 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $240.8 million (2024), against an average of $238.2 million.
- Across the five-year window, Total Current Liabilities soared 489.52% in 2022 and tumbled 54.55% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $295.1 million in 2022, then fell by 12.88% to $257.1 million in 2023, then fell by 10.62% to $229.8 million in 2024, then slumped by 37.99% to $142.5 million in 2025, then fell by 18.67% to $115.9 million in 2026.
- Per Business Quant, the three latest ARVN Total Current Liabilities figures stand at $115.9 million (Q1 2026), $142.5 million (Q4 2025), and $144.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 289.60 Mn |
| 10 | Arvinas | 512.64 Mn | -102.26 Mn | - | 115.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.90 Mn |
| Dec 31, 2025 | 142.50 Mn |
| Sep 30, 2025 | 144.90 Mn |
| Jun 30, 2025 | 157.80 Mn |
| Mar 31, 2025 | 214.00 Mn |
| Dec 31, 2024 | 229.80 Mn |
| Sep 30, 2024 | 275.90 Mn |
| Jun 30, 2024 | 347.20 Mn |
| Mar 31, 2024 | 240.80 Mn |
| Dec 31, 2023 | 257.10 Mn |
| Sep 30, 2023 | 317.30 Mn |
| Jun 30, 2023 | 306.90 Mn |
| Mar 31, 2023 | 282.90 Mn |
| Dec 31, 2022 | 295.10 Mn |
| Sep 30, 2022 | 244.60 Mn |
| Jun 30, 2022 | 238.20 Mn |
| Mar 31, 2022 | 238.00 Mn |
| Dec 31, 2021 | 261.70 Mn |
| Sep 30, 2021 | 182.51 Mn |
| Jun 30, 2021 | 41.82 Mn |